Skip to main content

Table 1 Baseline characteristics of study participants at enrolment

From: Pyronaridine–artesunate and artemether–lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a randomized controlled non-inferiority trial

 

Pyronaridine–artesunate

(n = 101)

Artemether–lumefantrine

(n = 96)

Male sex, n (%)

53 (52.5)

48 (50.0)

Mean age, years (SD) [range]

6.9 (2.9) [1.6–12]

6.4 (3.3) [0.9–12]

Age category, years, n (%)

 ≤ 1

0

2 (2.1)

 > 1 to < 5

31 (30.7)

31 (32.3)

 5–12

70 (69.3)

63 (65.6)

Mean weight, kg (SD) [range]

23.0 (8.4) [10–44]

22.4 (9.2) [8.5–45]

Mean hemoglobin, g/dL (SD) [range]

11.8 (1.9) [6.2–15.8]

11.9 (2.1) [6.8–16.4]

Mean temperature,  °C (SD) [range]

37.5 (1.2) [35.1–39.8]

37.3 (1.2) [35.2–39.9]

Fever (temperature > 37.5 °C), n (%)

53 (52.5)

40 (41.7)

Geometric mean asexual parasitaemia, µL−1 (95% CI)

24,420.6 (18,837.6–31,658.3)

23,672.5 (18,576.2–30,167.0)

Gametocyte prevalence-microscopy, n (%)

2 (1.98)

4 (4.17)